Rabinovich Alex, Ramanakumar Agnihotram V, Lau Susie, Gotlieb Walter H
Division of Gynecologic Oncology, Segal Cancer Center, Jewish General Hospital, Lady Davis Research Institute, Montreal, Quebec, Canada.
Division of Cancer Epidemiology, Department of Oncology, McGill University, Montreal, Quebec, Canada.
Acta Obstet Gynecol Scand. 2015 Jul;94(7):776-780. doi: 10.1111/aogs.12642. Epub 2015 Apr 28.
We conducted a proof of concept study evaluating prolonged treatment with pegylated liposomal doxorubicin for recurrent ovarian, tubal and peritoneal carcinoma. Thirteen consecutive patients received an average of 22.6 cycles of pegylated liposomal doxorubicin, with an average cumulative dose of 1409 mg/m(2) . Progression-free survival at 18 months was 61.5%, and was longer than the previous progression-free survival in 10 of the 13 patients. Overall 5-year survival was 78.8%. Despite prolonged use and relatively large cumulative doses of pegylated liposomal doxorubicin, most of the patients had mild to moderate side-effects, none of the patients had detectable cardio-toxic side-effects, and a positive impact on the performance status was noticed. Thus, in our group of patients, continued pegylated liposomal doxorubicin treatment was associated with a longer progression-free interval and allowed improved performance status with manageable toxicity.
我们开展了一项概念验证研究，评估聚乙二醇化脂质体阿霉素对复发性卵巢癌、输卵管癌和腹膜癌的长期治疗效果。连续13例患者平均接受了22.6个周期的聚乙二醇化脂质体阿霉素治疗，平均累积剂量为1409mg/m²。18个月时的无进展生存率为61.5%，13例患者中有10例的无进展生存期长于之前。总体5年生存率为78.8%。尽管长期使用且聚乙二醇化脂质体阿霉素累积剂量相对较大，但大多数患者出现轻至中度副作用，无患者出现可检测到的心脏毒性副作用，且观察到对体能状态有积极影响。因此，在我们的患者组中，持续使用聚乙二醇化脂质体阿霉素治疗与更长的无进展间期相关，且能在毒性可控的情况下改善体能状态。
